rrx 001 Search Results


rrx 001  (MedChemExpress)
95
MedChemExpress rrx 001
Figure 2. G6PD inhibition reduces malignancy and resistance to MRTX1133 in KRASG12D-mutated PDAC (A) Heatmap illustrating organoid area fold changes and synergy indexes with MRTX1133 following treatment with the indicated inhibitors. Measurements taken 6 days post treatment. Organoid area fold changes and synergy indexes are represented by the indicated values of different colors and sizes. (B) Synergy analysis <t>of</t> <t>RRx-001</t> and MRTX1133 using the Loewe model in KPC organoids. (C–E) Representative images of pancreatic tissues from KC mice stained with H&E, Alcian blue, and amylase/CK19 with or without RRx-001 treatment (5 mg/kg/ day) (C). Quantification of the total (D) and differential-grade (E) area of precancerous lesions in the entire pancreatic tissue section (n = 6). (F) Representative images and quantification of pan-keratin and Ki67 staining in PDAC tissues from KPC allografts and PDX-1 models, with and without RRx-001 treatment (5 mg/kg/day) (n = 6). (G and H) Tumor growth of KPC allografts (G) and PDX-1 (H) models with or without RRx-001 (n = 6). (I–L) Tumor growth and survival analysis of KPC allografts (I and J) and PDX-1 (K and L) models treated with RRx-001 (5 mg/kg/day) and/or MRTX1133 (30 mg/kg/ day) (n = 6).
Rrx 001, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rrx+001/RRx-001/pm39970873-278-4-5
Average 95 stars, based on 1 article reviews
rrx 001 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
g6pd inhibitor rrx 001  (TargetMol)
94
TargetMol g6pd inhibitor rrx 001
Figure 2. G6PD inhibition reduces malignancy and resistance to MRTX1133 in KRASG12D-mutated PDAC (A) Heatmap illustrating organoid area fold changes and synergy indexes with MRTX1133 following treatment with the indicated inhibitors. Measurements taken 6 days post treatment. Organoid area fold changes and synergy indexes are represented by the indicated values of different colors and sizes. (B) Synergy analysis <t>of</t> <t>RRx-001</t> and MRTX1133 using the Loewe model in KPC organoids. (C–E) Representative images of pancreatic tissues from KC mice stained with H&E, Alcian blue, and amylase/CK19 with or without RRx-001 treatment (5 mg/kg/ day) (C). Quantification of the total (D) and differential-grade (E) area of precancerous lesions in the entire pancreatic tissue section (n = 6). (F) Representative images and quantification of pan-keratin and Ki67 staining in PDAC tissues from KPC allografts and PDX-1 models, with and without RRx-001 treatment (5 mg/kg/day) (n = 6). (G and H) Tumor growth of KPC allografts (G) and PDX-1 (H) models with or without RRx-001 (n = 6). (I–L) Tumor growth and survival analysis of KPC allografts (I and J) and PDX-1 (K and L) models treated with RRx-001 (5 mg/kg/day) and/or MRTX1133 (30 mg/kg/ day) (n = 6).
G6pd Inhibitor Rrx 001, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rrx+001/RRX-001/pm41115561-43-4-20
Average 94 stars, based on 1 article reviews
g6pd inhibitor rrx 001 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
rrx 001  (Selleck Chemicals)
94
Selleck Chemicals rrx 001
Figure 2. G6PD inhibition reduces malignancy and resistance to MRTX1133 in KRASG12D-mutated PDAC (A) Heatmap illustrating organoid area fold changes and synergy indexes with MRTX1133 following treatment with the indicated inhibitors. Measurements taken 6 days post treatment. Organoid area fold changes and synergy indexes are represented by the indicated values of different colors and sizes. (B) Synergy analysis <t>of</t> <t>RRx-001</t> and MRTX1133 using the Loewe model in KPC organoids. (C–E) Representative images of pancreatic tissues from KC mice stained with H&E, Alcian blue, and amylase/CK19 with or without RRx-001 treatment (5 mg/kg/ day) (C). Quantification of the total (D) and differential-grade (E) area of precancerous lesions in the entire pancreatic tissue section (n = 6). (F) Representative images and quantification of pan-keratin and Ki67 staining in PDAC tissues from KPC allografts and PDX-1 models, with and without RRx-001 treatment (5 mg/kg/day) (n = 6). (G and H) Tumor growth of KPC allografts (G) and PDX-1 (H) models with or without RRx-001 (n = 6). (I–L) Tumor growth and survival analysis of KPC allografts (I and J) and PDX-1 (K and L) models treated with RRx-001 (5 mg/kg/day) and/or MRTX1133 (30 mg/kg/ day) (n = 6).
Rrx 001, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rrx+001/RRx-001/pm34419499-71-38-39
Average 94 stars, based on 1 article reviews
rrx 001 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
rrx-001  (EpicentRx)
90
EpicentRx rrx-001
Figure 2. G6PD inhibition reduces malignancy and resistance to MRTX1133 in KRASG12D-mutated PDAC (A) Heatmap illustrating organoid area fold changes and synergy indexes with MRTX1133 following treatment with the indicated inhibitors. Measurements taken 6 days post treatment. Organoid area fold changes and synergy indexes are represented by the indicated values of different colors and sizes. (B) Synergy analysis <t>of</t> <t>RRx-001</t> and MRTX1133 using the Loewe model in KPC organoids. (C–E) Representative images of pancreatic tissues from KC mice stained with H&E, Alcian blue, and amylase/CK19 with or without RRx-001 treatment (5 mg/kg/ day) (C). Quantification of the total (D) and differential-grade (E) area of precancerous lesions in the entire pancreatic tissue section (n = 6). (F) Representative images and quantification of pan-keratin and Ki67 staining in PDAC tissues from KPC allografts and PDX-1 models, with and without RRx-001 treatment (5 mg/kg/day) (n = 6). (G and H) Tumor growth of KPC allografts (G) and PDX-1 (H) models with or without RRx-001 (n = 6). (I–L) Tumor growth and survival analysis of KPC allografts (I and J) and PDX-1 (K and L) models treated with RRx-001 (5 mg/kg/day) and/or MRTX1133 (30 mg/kg/ day) (n = 6).
Rrx 001, supplied by EpicentRx, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rrx+001/rrx+001/pmc09169989-190-12-8
Average 90 stars, based on 1 article reviews
rrx-001 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
rrx-001  (BioMimetic Therapeutics)
90
BioMimetic Therapeutics rrx-001
Figure 2. G6PD inhibition reduces malignancy and resistance to MRTX1133 in KRASG12D-mutated PDAC (A) Heatmap illustrating organoid area fold changes and synergy indexes with MRTX1133 following treatment with the indicated inhibitors. Measurements taken 6 days post treatment. Organoid area fold changes and synergy indexes are represented by the indicated values of different colors and sizes. (B) Synergy analysis <t>of</t> <t>RRx-001</t> and MRTX1133 using the Loewe model in KPC organoids. (C–E) Representative images of pancreatic tissues from KC mice stained with H&E, Alcian blue, and amylase/CK19 with or without RRx-001 treatment (5 mg/kg/ day) (C). Quantification of the total (D) and differential-grade (E) area of precancerous lesions in the entire pancreatic tissue section (n = 6). (F) Representative images and quantification of pan-keratin and Ki67 staining in PDAC tissues from KPC allografts and PDX-1 models, with and without RRx-001 treatment (5 mg/kg/day) (n = 6). (G and H) Tumor growth of KPC allografts (G) and PDX-1 (H) models with or without RRx-001 (n = 6). (I–L) Tumor growth and survival analysis of KPC allografts (I and J) and PDX-1 (K and L) models treated with RRx-001 (5 mg/kg/day) and/or MRTX1133 (30 mg/kg/ day) (n = 6).
Rrx 001, supplied by BioMimetic Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rrx+001/rrx+001/pmc11889221-1569-3-21
Average 90 stars, based on 1 article reviews
rrx-001 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
rrx-001  (RadioRx Inc)
90
RadioRx Inc rrx-001
Figure 2. G6PD inhibition reduces malignancy and resistance to MRTX1133 in KRASG12D-mutated PDAC (A) Heatmap illustrating organoid area fold changes and synergy indexes with MRTX1133 following treatment with the indicated inhibitors. Measurements taken 6 days post treatment. Organoid area fold changes and synergy indexes are represented by the indicated values of different colors and sizes. (B) Synergy analysis <t>of</t> <t>RRx-001</t> and MRTX1133 using the Loewe model in KPC organoids. (C–E) Representative images of pancreatic tissues from KC mice stained with H&E, Alcian blue, and amylase/CK19 with or without RRx-001 treatment (5 mg/kg/ day) (C). Quantification of the total (D) and differential-grade (E) area of precancerous lesions in the entire pancreatic tissue section (n = 6). (F) Representative images and quantification of pan-keratin and Ki67 staining in PDAC tissues from KPC allografts and PDX-1 models, with and without RRx-001 treatment (5 mg/kg/day) (n = 6). (G and H) Tumor growth of KPC allografts (G) and PDX-1 (H) models with or without RRx-001 (n = 6). (I–L) Tumor growth and survival analysis of KPC allografts (I and J) and PDX-1 (K and L) models treated with RRx-001 (5 mg/kg/day) and/or MRTX1133 (30 mg/kg/ day) (n = 6).
Rrx 001, supplied by RadioRx Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rrx+001/rrx+001/pmc03431031-51-4-25
Average 90 stars, based on 1 article reviews
rrx-001 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
rrx-001  (NanoCarrier Co)
90
NanoCarrier Co rrx-001
Figure 2. G6PD inhibition reduces malignancy and resistance to MRTX1133 in KRASG12D-mutated PDAC (A) Heatmap illustrating organoid area fold changes and synergy indexes with MRTX1133 following treatment with the indicated inhibitors. Measurements taken 6 days post treatment. Organoid area fold changes and synergy indexes are represented by the indicated values of different colors and sizes. (B) Synergy analysis <t>of</t> <t>RRx-001</t> and MRTX1133 using the Loewe model in KPC organoids. (C–E) Representative images of pancreatic tissues from KC mice stained with H&E, Alcian blue, and amylase/CK19 with or without RRx-001 treatment (5 mg/kg/ day) (C). Quantification of the total (D) and differential-grade (E) area of precancerous lesions in the entire pancreatic tissue section (n = 6). (F) Representative images and quantification of pan-keratin and Ki67 staining in PDAC tissues from KPC allografts and PDX-1 models, with and without RRx-001 treatment (5 mg/kg/day) (n = 6). (G and H) Tumor growth of KPC allografts (G) and PDX-1 (H) models with or without RRx-001 (n = 6). (I–L) Tumor growth and survival analysis of KPC allografts (I and J) and PDX-1 (K and L) models treated with RRx-001 (5 mg/kg/day) and/or MRTX1133 (30 mg/kg/ day) (n = 6).
Rrx 001, supplied by NanoCarrier Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rrx+001/rrx+001/pmc10640620__41467_2023_42972_MOESM2_ESM-404-5-8
Average 90 stars, based on 1 article reviews
rrx-001 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
rrx-001  (Informa UK Limited)
90
Informa UK Limited rrx-001
Figure 2. G6PD inhibition reduces malignancy and resistance to MRTX1133 in KRASG12D-mutated PDAC (A) Heatmap illustrating organoid area fold changes and synergy indexes with MRTX1133 following treatment with the indicated inhibitors. Measurements taken 6 days post treatment. Organoid area fold changes and synergy indexes are represented by the indicated values of different colors and sizes. (B) Synergy analysis <t>of</t> <t>RRx-001</t> and MRTX1133 using the Loewe model in KPC organoids. (C–E) Representative images of pancreatic tissues from KC mice stained with H&E, Alcian blue, and amylase/CK19 with or without RRx-001 treatment (5 mg/kg/ day) (C). Quantification of the total (D) and differential-grade (E) area of precancerous lesions in the entire pancreatic tissue section (n = 6). (F) Representative images and quantification of pan-keratin and Ki67 staining in PDAC tissues from KPC allografts and PDX-1 models, with and without RRx-001 treatment (5 mg/kg/day) (n = 6). (G and H) Tumor growth of KPC allografts (G) and PDX-1 (H) models with or without RRx-001 (n = 6). (I–L) Tumor growth and survival analysis of KPC allografts (I and J) and PDX-1 (K and L) models treated with RRx-001 (5 mg/kg/day) and/or MRTX1133 (30 mg/kg/ day) (n = 6).
Rrx 001, supplied by Informa UK Limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rrx+001/rrx+001/pm33306414-2-49-20
Average 90 stars, based on 1 article reviews
rrx-001 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
rrx-001  (Coldstream Laboratories)
90
Coldstream Laboratories rrx-001
Figure 2. G6PD inhibition reduces malignancy and resistance to MRTX1133 in KRASG12D-mutated PDAC (A) Heatmap illustrating organoid area fold changes and synergy indexes with MRTX1133 following treatment with the indicated inhibitors. Measurements taken 6 days post treatment. Organoid area fold changes and synergy indexes are represented by the indicated values of different colors and sizes. (B) Synergy analysis <t>of</t> <t>RRx-001</t> and MRTX1133 using the Loewe model in KPC organoids. (C–E) Representative images of pancreatic tissues from KC mice stained with H&E, Alcian blue, and amylase/CK19 with or without RRx-001 treatment (5 mg/kg/ day) (C). Quantification of the total (D) and differential-grade (E) area of precancerous lesions in the entire pancreatic tissue section (n = 6). (F) Representative images and quantification of pan-keratin and Ki67 staining in PDAC tissues from KPC allografts and PDX-1 models, with and without RRx-001 treatment (5 mg/kg/day) (n = 6). (G and H) Tumor growth of KPC allografts (G) and PDX-1 (H) models with or without RRx-001 (n = 6). (I–L) Tumor growth and survival analysis of KPC allografts (I and J) and PDX-1 (K and L) models treated with RRx-001 (5 mg/kg/day) and/or MRTX1133 (30 mg/kg/ day) (n = 6).
Rrx 001, supplied by Coldstream Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rrx+001/rrx+001/10__1016_slash_s1470___2045_ascii40_15_ascii41_00089___3-44-0-13
Average 90 stars, based on 1 article reviews
rrx-001 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
rrx-001  (Verlag GmbH)
90
Verlag GmbH rrx-001
Figure 2. G6PD inhibition reduces malignancy and resistance to MRTX1133 in KRASG12D-mutated PDAC (A) Heatmap illustrating organoid area fold changes and synergy indexes with MRTX1133 following treatment with the indicated inhibitors. Measurements taken 6 days post treatment. Organoid area fold changes and synergy indexes are represented by the indicated values of different colors and sizes. (B) Synergy analysis <t>of</t> <t>RRx-001</t> and MRTX1133 using the Loewe model in KPC organoids. (C–E) Representative images of pancreatic tissues from KC mice stained with H&E, Alcian blue, and amylase/CK19 with or without RRx-001 treatment (5 mg/kg/ day) (C). Quantification of the total (D) and differential-grade (E) area of precancerous lesions in the entire pancreatic tissue section (n = 6). (F) Representative images and quantification of pan-keratin and Ki67 staining in PDAC tissues from KPC allografts and PDX-1 models, with and without RRx-001 treatment (5 mg/kg/day) (n = 6). (G and H) Tumor growth of KPC allografts (G) and PDX-1 (H) models with or without RRx-001 (n = 6). (I–L) Tumor growth and survival analysis of KPC allografts (I and J) and PDX-1 (K and L) models treated with RRx-001 (5 mg/kg/day) and/or MRTX1133 (30 mg/kg/ day) (n = 6).
Rrx 001, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rrx+001/rrx+001/pm32468692-26-18-11
Average 90 stars, based on 1 article reviews
rrx-001 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
rrx 001  (Cayman Chemical)
N/A
RRX 001
   Buy from Supplier
rrx-001  (1PlusChem LLC)
N/A
RRX-001
   Buy from Supplier

Image Search Results


Figure 2. G6PD inhibition reduces malignancy and resistance to MRTX1133 in KRASG12D-mutated PDAC (A) Heatmap illustrating organoid area fold changes and synergy indexes with MRTX1133 following treatment with the indicated inhibitors. Measurements taken 6 days post treatment. Organoid area fold changes and synergy indexes are represented by the indicated values of different colors and sizes. (B) Synergy analysis of RRx-001 and MRTX1133 using the Loewe model in KPC organoids. (C–E) Representative images of pancreatic tissues from KC mice stained with H&E, Alcian blue, and amylase/CK19 with or without RRx-001 treatment (5 mg/kg/ day) (C). Quantification of the total (D) and differential-grade (E) area of precancerous lesions in the entire pancreatic tissue section (n = 6). (F) Representative images and quantification of pan-keratin and Ki67 staining in PDAC tissues from KPC allografts and PDX-1 models, with and without RRx-001 treatment (5 mg/kg/day) (n = 6). (G and H) Tumor growth of KPC allografts (G) and PDX-1 (H) models with or without RRx-001 (n = 6). (I–L) Tumor growth and survival analysis of KPC allografts (I and J) and PDX-1 (K and L) models treated with RRx-001 (5 mg/kg/day) and/or MRTX1133 (30 mg/kg/ day) (n = 6).

Journal: Cell reports. Medicine

Article Title: KRAS G12D -driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC.

doi: 10.1016/j.xcrm.2025.101966

Figure Lengend Snippet: Figure 2. G6PD inhibition reduces malignancy and resistance to MRTX1133 in KRASG12D-mutated PDAC (A) Heatmap illustrating organoid area fold changes and synergy indexes with MRTX1133 following treatment with the indicated inhibitors. Measurements taken 6 days post treatment. Organoid area fold changes and synergy indexes are represented by the indicated values of different colors and sizes. (B) Synergy analysis of RRx-001 and MRTX1133 using the Loewe model in KPC organoids. (C–E) Representative images of pancreatic tissues from KC mice stained with H&E, Alcian blue, and amylase/CK19 with or without RRx-001 treatment (5 mg/kg/ day) (C). Quantification of the total (D) and differential-grade (E) area of precancerous lesions in the entire pancreatic tissue section (n = 6). (F) Representative images and quantification of pan-keratin and Ki67 staining in PDAC tissues from KPC allografts and PDX-1 models, with and without RRx-001 treatment (5 mg/kg/day) (n = 6). (G and H) Tumor growth of KPC allografts (G) and PDX-1 (H) models with or without RRx-001 (n = 6). (I–L) Tumor growth and survival analysis of KPC allografts (I and J) and PDX-1 (K and L) models treated with RRx-001 (5 mg/kg/day) and/or MRTX1133 (30 mg/kg/ day) (n = 6).

Article Snippet: For drug intervention studies, RRx-001 (MCE, #HY-16438) was intraperitoneally administered every other day at a dosage of 5mg/kg, whereas PGG (MCE, #HY-N0527) was orally administered at a dosage of 40 mg/kg/day.

Techniques: Inhibition, Staining